WALTHAM, Mass. - Officials at Maxxim Medical, Inc. say they have signed a five-year contract with AmeriNet Choice for the healthcare organization's can liner business.
Maxxim Medical will provide the company with hamper and biohazard bags -- a deal estimated at $4 million annually, for a potential $20 million during the contract.
Jeff Urbany, vice president of Maxxim Medical says the company is prepared for the agreement to begin.
"We are pleased to have been awarded the contract for AmeriNet Choice Can Liners," he says. "Our experience in this area provides their facilities with the opportunity to review standardization and utilization procedures as a way to enhance savings opportunities. Moreover, our wide product offering provides us the ability to cross-reference to any existing liner."
Maxxim Medical also manufactures disposable medical products and a range of specialty medical products that include custom surgical procedural trays and vascular devices.
AmeriNet, Inc., operates three shareholder healthcare organizations: AmeriNet Central, Intermountain Health Care and Vector. This grouping represents 14,568 facilities in 50 states.
Managerial Challenges: Setting Boundaries and Priorities in the Workplace
May 3rd 2024Maintaining boundaries can be challenging in a culture of overwork. In this installment of Dear Helpdesk, learn how to communicate effectively with your boss, prioritize your values, and safeguard your work-life balance.
Comprehensive Guide to Lymphedema: Causes, Prevention, and Management Strategies
May 3rd 2024Lymphedema, a chronic condition often stemming from cancer treatments, leads to tissue swelling. Early detection through surveillance programs and proper skincare can prevent complications like infections.
Advancing Viral Disease Treatment of Recurrent Genital Herpes, Hepatitis B and D Viruses
May 2nd 2024Health care has an unmet need for the treatment of herpesviruses, hepatitis B, and hepatitis D, which would enhance patient outcomes. What should be done, and what challenges do companies that are trying to develop treatments face?